Akero Therapeutics — Technical Presentation (September 2022)
21 slides from Akero Therapeutics's technical presentation, Sep 13, 2022
Slide 1: Phase 2b HARMONY Study Results
Phase 2b HARMONY Study Results Restoring Balance. Renewing Life. September 13, 2022 Exhibit 99.2
Slide 2: Safe Harbor
Safe Harbor ©2022 AKERO THERAPEUTICS. This presentation and the accompanying oral commentary may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our b
Slide 3: Evaluating efruxifermin (EFX), An Fc-FGF21 Fusion Protein
Evaluating efruxifermin (EFX), An Fc-FGF21 Fusion Protein ©2022 AKERO THERAPEUTICS. Statistically Significant Effects after 24 Weeks Fibrosis Improvement NASH Resolution Fibrosis Improvement AND NASH Resolution
Slide 4: HARMONY Trial Design: Pre-Cirrhotic (F2-F3) NASH
HARMONY Trial Design: Pre-Cirrhotic (F2-F3) NASH ©2022 AKERO THERAPEUTICS. MRI-PDFF Liver Biopsy Screening Randomization EFX 28mg Placebo 24 Weeks EFX 50mg Placebo EFX Continuation Dose TBD Long-Term Safety Follow-Up Phase 2b Key Inclusion Criteria F2-F3 NASH NAS ≥4 Liver Fat (MRI-PDFF) ≥8% Phase 2b
Slide 5: Patient Disposition & Analysis Sets
Week 24 Patient Disposition & Analysis Sets ©2022 AKERO THERAPEUTICS. Randomized (N=128) Completed Week 24 (N=115) Biopsies Collected (N=113) Randomized Not Dosed EFX (N=2) Discontinued Prior to Week 24 (N=11) Dosed (N=126) Due to AEs EFX (N=5) Administrative EFX (N=5) Placebo (N=1) Biopsies Not Col
Slide 6: Baseline Demographics
Baseline Demographics ©2022 AKERO THERAPEUTICS. Parameter (Mean) Placebo (N=43) EFX 28mg (N=42) EFX 50mg (N=43) Age (Years) 55 57 52 Sex (% Female) 63 69 53 Weight (kg) 108 104 103 Type 2 Diabetes (%) 65 76 70 Fibrosis Stage (% F3)1 70 64 63 Enhanced Liver Fibrosis (ELF) Score 9.8 9.7 9.8 Pro-C32 (μ
Slide 7: Consensus Reading of Biopsies: Rigorous Approach to Histopathology
Consensus Reading of Biopsies: Rigorous Approach to Histopathology Based on FDA Input to Minimize Variability ©2022 AKERO THERAPEUTICS. Different Scores Slides Prepared From Tissue Samples Score 1 Score 2 Same Score Consensus Score Adjudicated Score No Consensus Consensus Meeting Final Score QC’d an
Slide 8: Both EFX Doses Achieved Statistical Significance on Primary Endpoint (Fibrosis Improvement)
Both EFX Doses Achieved Statistical Significance on Primary Endpoint (Fibrosis Improvement) ©2022 AKERO THERAPEUTICS. Source Data: Liver Biopsy Analysis Set *39%* Fibrosis Improvement ≥1 Stage & No Worsening of NASH1 at Week 24 1 Improvement in liver fibrosis greater than or equal to one stage and n
Slide 9: EFX Fibrosis Improvement in Context: Pre-Cirrhotic NASH
*** Obeticholic Acid Phase 3 (F2-F3) 54% F3 72 Wks / ITT3 Consensus Readers Placebo 10% 14% 22% (N=311) (N=308) (N=312) 10mg 25mg 12% 4% Akero Efruxifermin Phase 2b (F2-F3) 66% F3 24 Wks / Completers1 Consensus Readers (N=41) (N=34) (N=38) 41% 39% 2% 28mg 50mg Placebo * * 20%† 21% EFX Fibrosis Impro
Slide 10: Both EFX Doses Achieved Statistical Significance on Key Secondary Endpoint (NASH Resolution)
Both EFX Doses Achieved Statistical Significance on Key Secondary Endpoint (NASH Resolution) ©2022 AKERO THERAPEUTICS. Source Data: Liver Biopsy Analysis Set 1 NAS score of 0 or 1 for lobular inflammation and a score of 0 for ballooning NASH Resolution1 & No Worsening of Fibrosis at Week 24 EFX 28mg
Slide 11: NASH Resolution in Context: Pre-Cirrhotic NASH
Novo Nordisk Semaglutide Phase 2b (F2-F3) 69% F3 72 Wks / ITT2 Consensus Readers EFX NASH Resolution in Context: Pre-Cirrhotic NASH (NASH Resolution and No Worsening of Fibrosis) ©2022 AKERO THERAPEUTICS. 32% (N=19) 27mg * p<0.05, ** p<0.01, *** p<0.001, versus placebo Note: These data are derived f
Slide 12: Both EFX Doses Achieved Statistical Significance on Composite Endpoint
Both EFX Doses Achieved Statistical Significance on Composite Endpoint (Fibrosis Improvement and NASH Resolution) ©2022 AKERO THERAPEUTICS. Source Data: Liver Biopsy Analysis Set 1 Improvement in liver fibrosis greater than or equal to one stage 2 NAS score of 0 or 1 for lobular inflammation and a s
Slide 13: Magnitude of Reduction and Normalization of Liver Fat
EFX 50mg Endpoint Placebo (N=42) EFX 28mg (N=38) EFX 50mg (N=35) Relative Reduction in Liver Fat ≥50% 2% 63% *** 77% *** Normalization of Liver Fat Content ≤5% 2% 34% *** 51% *** Magnitude of Reduction and Normalization of Liver Fat Comparable to Phase 2a BALANCED Study1 ©2022 AKERO THERAPEUTICS. Pr
Slide 14: Rapid and Sustained Improvements in Markers of Liver Injury
Rapid and Sustained Statistically Significant Improvements in Markers of Liver Injury ©2022 AKERO THERAPEUTICS. ALT, LS Mean Percent Change from Baseline AST, LS Mean Percent Change from Baseline ** p<0.01, *** p<0.001, versus placebo (MMRM1) *** p<0.001, versus placebo (MMRM1) Source Data: Full Ana
Slide 15: Reductions in Non-Invasive Markers Reflect Histological Improvement in Fibrosis
†-2.6† -2.6 ***-5.1*** Liver Stiffness by FibroScan (kPa) EFX 28 mg Placebo N=38 N=42 EFX 50mg N=36 -0.7 ** p<0.01, versus placebo (ANCOVA1) † p<0.01, versus baseline (ANCOVA) ELF Score EFX 28 mg Placebo N=37 N=42 EFX 50mg N=34 +0.1 *** p<0.001, versus placebo (MMRM1) -5.1 EFX 28mg Placebo N=37 N=40
Slide 16: Treatment-Emergent Adverse Events (TEAE)
Treatment-Emergent Adverse Events (TEAE) ©2022 AKERO THERAPEUTICS. TEAE Overview Placebo (N=43) EFX 28mg (N=40) EFX 50mg (N=43) TEAE Leading to Death 0 (0%) 0 (0%) 0 (0%) Drug-Related Serious Adverse Event (SAE) 0 (0%) 0 (0%) 1 (2%)a,b TEAE Leading to Discontinuation 0 (0%) 2 (5%)c 3 (7%)d Most Freq
Slide 17: Improvements in Glycemic Control and Insulin Sensitivity
+16% Placebo EFX 28mg EFX 50mg N=28 N=26 N=26 T2D Subset +9% Placebo EFX 28mg EFX 50mg N=37 N=41 N=35 All All EFX 50mg 0.0 Placebo EFX 28mg N=37 N=42 N=36 T2D Subset 0.0 Placebo EFX 28mg EFX 50mg N=28 N=27 N=27 Clinically Meaningful Improvements Observed in Glycemic Control and Insulin Sensitivity,
Slide 18: Significant Improvements Observed in Lipoprotein Profile
HDL Cholesterol *** p<0.001, versus placebo (MMRM) -2% Placebo EFX 28mg EFX 50mg N=35 N=42 N=35 LDL Cholesterol ** p<0.01, versus placebo (MMRM) +9% Placebo EFX 28mg EFX 50mg N=35 N=42 N=35 Significant Improvements Observed in Lipoprotein Profile ©2022 AKERO THERAPEUTICS. LS Mean Change From Baselin
Slide 19: Weight Loss Observed for 50mg EFX Dose Group
Weight Loss Observed for 50mg EFX Dose Group ©2022 AKERO THERAPEUTICS. Source Data: Full Analysis Set, non-missing values only, no imputation -0.2 Body Weight, LS Mean Change at Week 24 (kg) Placebo EFX 28mg EFX 50mg -0.6 N=37 N=42 N=36 -2.6%†† †† p<0.01, versus baseline (MMRM) ††-2.9†† -2.9
Slide 20: EFX: A Potentially Foundational NASH Therapy
©2022 AKERO THERAPEUTICS. addressing all core aspects of NASH pathogenesis in a single treatment Fibrosis Improvement NASH Resolution Fibrosis Improvement AND NASH Resolution Healthy Metabolism Restoration Liver Health Improvement After 24 Weeks EFX: A Potentially Foundational NASH Therapy
Slide 21: Akero Therapeutics
AKERO THERAPEUTICS 601 Gateway Boulevard Suite 350 South San Francisco, CA 94080
Akero Therapeutics — Technical Presentation (September 2022) on 6ix